Combination of Serum Test and Questionnaire in Early Gastric Cancer Screening
-
Qiang Li
,
Yibing Liu
,
Zhe Meng
,
Qingfeng Ge
,
Liyan Zhao
,
Huiying Chu
,
Xiaomin Li
,
Jingli Chen
,
Qingju Meng
Abstract
Background: We aimed to analyze the predictive role of serum test and questionnaire in Early Gastric Cancer in The First Affiliated Hospital of Xingtai Medical College, Hebei Province from 2019 to 2020.
Methods: In this prospective study, 280 medical examiners underwent questionnaire, serum test and gastroscopy. They were divided into Gastric cancer (GC) and Non-Gastric cancer (NGC) group. NGC group was divided into Low-grade intraepithelial neoplasia (LGIN), Chronic atrophic gastritis (CAG) and Non-chronic atrophic gastritis (NCAG) group.
Results: Age, drinking, sex and Gastrin-17(G-17) was respectively independent risk factors for GC. Age, drinking and G-17 was independent risk factors for GC in men. G-17 of GC group was higher than that of LGIN and NCAG group (P<0.05). Pepsinogen I/II ratio (PGR) of GC was lower than that of NCAG group (P<0.05). There was no significant difference between Pepsinogen I (PGⅠ) and Pepsinogen II (PGII) in the four groups. Helicobacter pylori-immunoglobulin G antibodies (H. pylori-IgG) of LGIN group was significantly higher than that of CAG and NCAG group in gastritis group (P<0.008). G-17≥42.95 pmol/L, age≥69years, male and drinking can predict GC.
Conclusion: Older, drinking, men and high G-17 could respectively predict GC. Especially in men, older, drinking and high G-17 could affect the occurrence of GC. G-17, age, drinking and sex used respectively to screen high-risk populations for GC were more efficient than combined screening. GC had a higher serum G-17 and a lower PG than other gastric diseases.
1. Ko JM, Tsang KH, Dai W, et al (2017). Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analy-sis for the Global Burden of Disease Study 2016. Lancet, 390(10100):1211-1259.
2. Correa P (2010). Serum pepsinogens in gas-tric cancer screening. Dig Dis Sci, 55(8):2123-5.
3. Sung H, Ferlay J, Siegel RL, et al (2021). Global Cancer Statistics 2020: GLO-BOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3):209-249.
4. Hamashima C, Goto R (2017). Potential ca-pacity of endoscopic screening for gastric cancer in Japan. Cancer Sci, 108(1):101-107.
5. Akbari M, Kardeh B, Tabrizi R, Ahmadizar F, Lankarani KB (2019). Incidence Rate of Gastric Cancer Adenocarcinoma in Patients with Gastric Dysplasia: A Sys-tematic Review and Meta-Analysis. J Clin Gastroenterol, 53(10):703-710.
6. Zheng KC, Aoki K, Li XQ, et al (2012). Serum pepsinogens, gastrin-17 and Helicobacter pylori antibody in the residents of two cities in china with distinct mortality rates of gastric cancer. Tohoku J Exp Med, 228(4):289-94.
7. Yamamichi N, Hirano C, Takahashi Y, et al (2016). Comparative analysis of upper gastrointestinal endoscopy, double-contrast upper gastrointestinal barium X-ray radiography, and the titer of serum anti-Helicobacter pylori IgG focusing on the diagnosis of atrophic gastritis. Gastric Cancer, 19(2): 670-675.
8. Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al (2019). Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Socie-ty of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Mi-crobiota Study Group (EHMSG), Euro-pean Society of Pathology (ESP), and So-ciedade Portuguesa de Endoscopia Di-gestiva (SPED) guideline update 2019. Endoscopy, 51(4):365-388.
9. Huang R, Chen SY, Chen JH (2020). Heli-cobacter pylori infection affects endos-copy signs of chronic atrophic gastritis border. Modern Digestion & Intervention, 25(03):320-324.
10. Shah SC, Nunez H, Chiu S, Hazan A, Chen S, Wang S, Itzkowitz S, Jandorf L (2020). Low baseline awareness of gastric cancer risk factors amongst at-risk multira-cial/ethnic populations in New York City: results of a targeted, culturally sensi-tive pilot gastric cancer community out-reach program. Ethn Health, 25(2):189-205.
11. Collatuzzo G, Pelucchi C, Negri E, et al (2021). Exploring the interactions be-tween Helicobacter pylori (Hp) infection and other risk factors of gastric cancer: A pooled analysis in the Stomach cancer Pooling (StoP) Project. Int J Cancer, 149(6):1228-1238.
12. Gong EJ, Ahn JY, Jung HY, et al (2014). Risk factors and clinical outcomes of gas-tric cancer identified by screening endos-copy: a case-control study. J Gastroenterol Hepatol, 29(2):301-309.
13. Rota M, Pelucchi C, Bertuccio P, et al (2017). Alcohol consumption and gastric cancer risk-A pooled analysis within the StoP project consortium. Int J Cancer, 141(10):1950-1962.
14. Chen S, Liu H, Li J, et al (2015). Risk of Gastric and Colorectal Cancer after Ta-moxifen Use for Breast Cancer: A Sys-tematic Review and Meta-Analysis. J Clin Gastroenterol, 49(8):666-74.
15. Liu Z, Li Z, Zhou Y, et al (2021). 2020 Global Cancer Statistics Report Interpre-tation. Tumor comprehensive therapy electronic magazine, 7(02): 1-14.
16. Xie S (2020). Multi-center forward-looking research of the risk factors of the esoph-agus and gastric gastrointestinal region of the high-incidence zone of China Gas-troenterology Cancer and the Dangerous Factor and Forecast Early Warning Logo. Beijing Union Medical College.
17. Lou L, Wang L, Zhang Y, et al (2020). Sex difference in incidence of gastric cancer: an international comparative study based on the Global Burden of Disease Study 2017. BMJ Open, 10(1): e033323.
18. Deng W, Jin L, Zhuo H, Vasiliou V, Zhang Y (2021). Alcohol consumption and risk of stomach cancer: A meta-analysis. Chem Biol Interact, 336: 109365.
19. Negri E, Pelucchi C, Bagnardi V, et al (2012). A meta-analysis on alcohol drinking and gastric cancer risk. Ann Oncol, 23(1): 28-36.
20. Wang Y, Zhu Z, Liu Z, et al (2020). Diag-nostic value of serum pepsinogen I, pep-sinogen II, and gastrin-17 levels for pop-ulation-based screening for early-stage gastric cancer. J Int Med Res, 48(3): 300060520914826.
21. Zhao WX, Liu ZF, Li XL, Li Z (2019). Cor-relations of serum homocysteine, VEGF and gastrin 17 with gastric cancer and precancerous lesions. Eur Rev Med Phar-macol Sci, 23(10): 4192-4198.
22. Dong Z, Zhang X, Chen X, Zhang J (2019). Significance of Serological Gastric Biopsy in Different Gastric Mucosal Le-sions: an Observational Study. Clin Lab, 65(12).
23. Zhuang K, Yan Y, Zhang X, Zhang J, Zhang L, Han K (2016). Gastrin pro-motes the metastasis of gastric carcinoma through the β-catenin/TCF-4 pathway. Oncol Rep, 36(3): 1369-1376.
24. Yi H. The diagnostic value of serum PG and G-17 in chronic atrophic gastritis and early gastric cancer [D]. Zhengzhou Uni-versity.
25. Shen H, Xiong K, Wu X, Cheng S, Lou Q, Jin H, Zhang X (2021). The Diagnostic Value of Serum Gastrin-17 and Pepsino-gen for Gastric Cancer Screening in Eastern China. Gastroenterol Res Pract, 2021:6894248.
26. Yu G, Wang GX, Wang HG, Mo FF, Tang BB (2019). The value of detecting pep-sinogen and gastrin-17 levels in serum for pre-cancerous lesion screening in gas-tric cancer. Neoplasma, 66(4):637-640.
27. Wang R, Chen XZ (2020). Prevalence of atrophic gastritis in southwest China and predictive strength of serum gastrin-17: A cross-sectional study (SIGES). Sci Rep, 10(1):4523.
28. Xie S, Wang S, Xue L, et al (2020). Helico-bacter pylori Is Associated With Precan-cerous and Cancerous Lesions of the Gastric Cardia Mucosa: Results of a Large Population-Based Study in China. Front Oncol, 10: 205.
29. Kumar S, Metz DC, Ellenberg S, Kaplan DE, Goldberg DS (2020). Risk Factors and Incidence of Gastric Cancer after Detection of Helicobacter pylori Infec-tion: A Large Cohort Study. Gastroenterolo-gy, 158(3):527-536.e7.
30. Cao Q, Ran ZH, Xiao SD (2007). Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Heli-cobacter pylori immunoglobulin G anti-bodies. J Dig Dis, 8(1):15-22.
31. Geng W, Zhang HY (2017). Research on the mechanism of HP mediated PI3K/AKT/GSK3β pathways in gastric cancer. Eur Rev Med Pharmacol Sci, 21(3 Suppl):33-37.
32. Xie Y, Liu L (2018). Analysis of correlation between HP infection and activation of PI3K/Akt pathway in mucosal tissues of gastric cancer and precancerous lesions. Oncol Lett, 16(5):5615-5620.
2. Correa P (2010). Serum pepsinogens in gas-tric cancer screening. Dig Dis Sci, 55(8):2123-5.
3. Sung H, Ferlay J, Siegel RL, et al (2021). Global Cancer Statistics 2020: GLO-BOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3):209-249.
4. Hamashima C, Goto R (2017). Potential ca-pacity of endoscopic screening for gastric cancer in Japan. Cancer Sci, 108(1):101-107.
5. Akbari M, Kardeh B, Tabrizi R, Ahmadizar F, Lankarani KB (2019). Incidence Rate of Gastric Cancer Adenocarcinoma in Patients with Gastric Dysplasia: A Sys-tematic Review and Meta-Analysis. J Clin Gastroenterol, 53(10):703-710.
6. Zheng KC, Aoki K, Li XQ, et al (2012). Serum pepsinogens, gastrin-17 and Helicobacter pylori antibody in the residents of two cities in china with distinct mortality rates of gastric cancer. Tohoku J Exp Med, 228(4):289-94.
7. Yamamichi N, Hirano C, Takahashi Y, et al (2016). Comparative analysis of upper gastrointestinal endoscopy, double-contrast upper gastrointestinal barium X-ray radiography, and the titer of serum anti-Helicobacter pylori IgG focusing on the diagnosis of atrophic gastritis. Gastric Cancer, 19(2): 670-675.
8. Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al (2019). Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Socie-ty of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Mi-crobiota Study Group (EHMSG), Euro-pean Society of Pathology (ESP), and So-ciedade Portuguesa de Endoscopia Di-gestiva (SPED) guideline update 2019. Endoscopy, 51(4):365-388.
9. Huang R, Chen SY, Chen JH (2020). Heli-cobacter pylori infection affects endos-copy signs of chronic atrophic gastritis border. Modern Digestion & Intervention, 25(03):320-324.
10. Shah SC, Nunez H, Chiu S, Hazan A, Chen S, Wang S, Itzkowitz S, Jandorf L (2020). Low baseline awareness of gastric cancer risk factors amongst at-risk multira-cial/ethnic populations in New York City: results of a targeted, culturally sensi-tive pilot gastric cancer community out-reach program. Ethn Health, 25(2):189-205.
11. Collatuzzo G, Pelucchi C, Negri E, et al (2021). Exploring the interactions be-tween Helicobacter pylori (Hp) infection and other risk factors of gastric cancer: A pooled analysis in the Stomach cancer Pooling (StoP) Project. Int J Cancer, 149(6):1228-1238.
12. Gong EJ, Ahn JY, Jung HY, et al (2014). Risk factors and clinical outcomes of gas-tric cancer identified by screening endos-copy: a case-control study. J Gastroenterol Hepatol, 29(2):301-309.
13. Rota M, Pelucchi C, Bertuccio P, et al (2017). Alcohol consumption and gastric cancer risk-A pooled analysis within the StoP project consortium. Int J Cancer, 141(10):1950-1962.
14. Chen S, Liu H, Li J, et al (2015). Risk of Gastric and Colorectal Cancer after Ta-moxifen Use for Breast Cancer: A Sys-tematic Review and Meta-Analysis. J Clin Gastroenterol, 49(8):666-74.
15. Liu Z, Li Z, Zhou Y, et al (2021). 2020 Global Cancer Statistics Report Interpre-tation. Tumor comprehensive therapy electronic magazine, 7(02): 1-14.
16. Xie S (2020). Multi-center forward-looking research of the risk factors of the esoph-agus and gastric gastrointestinal region of the high-incidence zone of China Gas-troenterology Cancer and the Dangerous Factor and Forecast Early Warning Logo. Beijing Union Medical College.
17. Lou L, Wang L, Zhang Y, et al (2020). Sex difference in incidence of gastric cancer: an international comparative study based on the Global Burden of Disease Study 2017. BMJ Open, 10(1): e033323.
18. Deng W, Jin L, Zhuo H, Vasiliou V, Zhang Y (2021). Alcohol consumption and risk of stomach cancer: A meta-analysis. Chem Biol Interact, 336: 109365.
19. Negri E, Pelucchi C, Bagnardi V, et al (2012). A meta-analysis on alcohol drinking and gastric cancer risk. Ann Oncol, 23(1): 28-36.
20. Wang Y, Zhu Z, Liu Z, et al (2020). Diag-nostic value of serum pepsinogen I, pep-sinogen II, and gastrin-17 levels for pop-ulation-based screening for early-stage gastric cancer. J Int Med Res, 48(3): 300060520914826.
21. Zhao WX, Liu ZF, Li XL, Li Z (2019). Cor-relations of serum homocysteine, VEGF and gastrin 17 with gastric cancer and precancerous lesions. Eur Rev Med Phar-macol Sci, 23(10): 4192-4198.
22. Dong Z, Zhang X, Chen X, Zhang J (2019). Significance of Serological Gastric Biopsy in Different Gastric Mucosal Le-sions: an Observational Study. Clin Lab, 65(12).
23. Zhuang K, Yan Y, Zhang X, Zhang J, Zhang L, Han K (2016). Gastrin pro-motes the metastasis of gastric carcinoma through the β-catenin/TCF-4 pathway. Oncol Rep, 36(3): 1369-1376.
24. Yi H. The diagnostic value of serum PG and G-17 in chronic atrophic gastritis and early gastric cancer [D]. Zhengzhou Uni-versity.
25. Shen H, Xiong K, Wu X, Cheng S, Lou Q, Jin H, Zhang X (2021). The Diagnostic Value of Serum Gastrin-17 and Pepsino-gen for Gastric Cancer Screening in Eastern China. Gastroenterol Res Pract, 2021:6894248.
26. Yu G, Wang GX, Wang HG, Mo FF, Tang BB (2019). The value of detecting pep-sinogen and gastrin-17 levels in serum for pre-cancerous lesion screening in gas-tric cancer. Neoplasma, 66(4):637-640.
27. Wang R, Chen XZ (2020). Prevalence of atrophic gastritis in southwest China and predictive strength of serum gastrin-17: A cross-sectional study (SIGES). Sci Rep, 10(1):4523.
28. Xie S, Wang S, Xue L, et al (2020). Helico-bacter pylori Is Associated With Precan-cerous and Cancerous Lesions of the Gastric Cardia Mucosa: Results of a Large Population-Based Study in China. Front Oncol, 10: 205.
29. Kumar S, Metz DC, Ellenberg S, Kaplan DE, Goldberg DS (2020). Risk Factors and Incidence of Gastric Cancer after Detection of Helicobacter pylori Infec-tion: A Large Cohort Study. Gastroenterolo-gy, 158(3):527-536.e7.
30. Cao Q, Ran ZH, Xiao SD (2007). Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Heli-cobacter pylori immunoglobulin G anti-bodies. J Dig Dis, 8(1):15-22.
31. Geng W, Zhang HY (2017). Research on the mechanism of HP mediated PI3K/AKT/GSK3β pathways in gastric cancer. Eur Rev Med Pharmacol Sci, 21(3 Suppl):33-37.
32. Xie Y, Liu L (2018). Analysis of correlation between HP infection and activation of PI3K/Akt pathway in mucosal tissues of gastric cancer and precancerous lesions. Oncol Lett, 16(5):5615-5620.
| Files | ||
| Issue | Vol 51 No 8 (2022) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v51i8.10267 | |
| Keywords | ||
| Gastrin-17 Helicobacter pylori Immunoglobulin G Pepsinogen Early gastric cancer | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Li Q, Liu Y, Meng Z, Ge Q, Zhao L, Chu H, Li X, Chen J, Meng Q. Combination of Serum Test and Questionnaire in Early Gastric Cancer Screening. Iran J Public Health. 2022;51(8):1817-1826.
